Problems with the endometrial lining are one of the leading causes of infertility in women.
Problems with the endometrial lining are one of the leading causes of infertility in women. The interior of the uterus is lined with a tissue called endometrium, which is prepared each month for the arrival of an embryo and is the place where the embryo implants and resides during gestation. When this does not occur, menstruation begins shedding the endometrial lining.

What is the endometrium?

Sometimes embryo implantation in the endometrium does not develop successfully. This failure can occur for different reasons. A particularly important factor is endometrial receptivity. The endometrium is receptive when it is ready for embryo implantation to occur. This period of receptivity is called the window of implantation.

Endometrial receptivity

ERA is a diagnostic method developed and patented by IGENOMIX R&D department since 2009, after more than 10 years of research. This technique allows us to evaluate the endometrial receptivity status of a woman.

This biopsy is quickly and easily taken by gynaecologists in their consultation room.

In our laboratory, the sequencing expression of 236 genes involved in the endometrial receptivity is analyzed. An in-house designed computational predictor analyzes the data obtained, classifying the endometrium as Receptive or Non-Receptive.

If receptive, the window of implantation (WOI) is defined as the day on which the biopsy was taken, meaning the embryo is capable of implantation in the uterus during this period of time.

A state of non receptivity means that the window of implantation is displaced.

The process may be repeated, according the recomendation given in the first non receptive result to validate your optimal WOI. Transferring an embryo at the optimal time maximizes your chances of achieving a pregnancy.

ERA is the first test developed to evaluate endometrial receptivity with published clinical efficiency

ERA links to a major improvement of the global pregnancy rate, up to 85%* in those personalized transfers made according to the test results.

What are the advantages?

Ask your gynaecologist for further information and to assess your case.

If you have any questions, contact us at: www.igenomix.com/era-form

How can I access ERA?

ERA is a diagnostic method developed and patented by IGENOMIX R&D department since 2009, after more than 10 years of research. This technique allows us to evaluate the endometrial receptivity status of a woman.

This biopsy is quickly and easily taken by gynaecologists in their consultation room.

In our laboratory, the sequencing expression of 236 genes involved in the endometrial receptivity is analyzed. An in-house designed computational predictor analyzes the data obtained, classifying the endometrium as Receptive or Non-Receptive.

If receptive, the window of implantation (WOI) is defined as the day on which the biopsy was taken, meaning the embryo is capable of implantation in the uterus during this period of time.

A state of non receptivity means that the window of implantation is displaced.

The process may be repeated, according the recomendation given in the first non receptive result to validate your optimal WOI. Transferring an embryo at the optimal time maximizes your chances of achieving a pregnancy.

ERA is the first test developed to evaluate endometrial receptivity with published clinical efficiency

ERA links to a major improvement of the global pregnancy rate, up to 85%* in those personalized transfers made according to the test results.

What are the advantages?

Ask your gynaecologist for further information and to assess your case.

If you have any questions, contact us at: www.igenomix.com/era-form

How can I access ERA?

ERA is a diagnostic method developed and patented by IGENOMIX R&D department since 2009, after more than 10 years of research. This technique allows us to evaluate the endometrial receptivity status of a woman.

This biopsy is quickly and easily taken by gynaecologists in their consultation room.

In our laboratory, the sequencing expression of 236 genes involved in the endometrial receptivity is analyzed. An in-house designed computational predictor analyzes the data obtained, classifying the endometrium as Receptive or Non-Receptive.

If receptive, the window of implantation (WOI) is defined as the day on which the biopsy was taken, meaning the embryo is capable of implantation in the uterus during this period of time.

A state of non receptivity means that the window of implantation is displaced.

The process may be repeated, according the recomendation given in the first non receptive result to validate your optimal WOI. Transferring an embryo at the optimal time maximizes your chances of achieving a pregnancy.

ERA is the first test developed to evaluate endometrial receptivity with published clinical efficiency

ERA links to a major improvement of the global pregnancy rate, up to 85%* in those personalized transfers made according to the test results.

What are the advantages?

Ask your gynaecologist for further information and to assess your case.

If you have any questions, contact us at: www.igenomix.com/era-form

How can I access ERA?

ERA is a diagnostic method developed and patented by IGENOMIX R&D department since 2009, after more than 10 years of research. This technique allows us to evaluate the endometrial receptivity status of a woman.

This biopsy is quickly and easily taken by gynaecologists in their consultation room.

In our laboratory, the sequencing expression of 236 genes involved in the endometrial receptivity is analyzed. An in-house designed computational predictor analyzes the data obtained, classifying the endometrium as Receptive or Non-Receptive.

If receptive, the window of implantation (WOI) is defined as the day on which the biopsy was taken, meaning the embryo is capable of implantation in the uterus during this period of time.

A state of non receptivity means that the window of implantation is displaced.

The process may be repeated, according the recomendation given in the first non receptive result to validate your optimal WOI. Transferring an embryo at the optimal time maximizes your chances of achieving a pregnancy.

ERA is the first test developed to evaluate endometrial receptivity with published clinical efficiency

ERA links to a major improvement of the global pregnancy rate, up to 85%* in those personalized transfers made according to the test results.

What are the advantages?

Ask your gynaecologist for further information and to assess your case.

If you have any questions, contact us at: www.igenomix.com/era-form

How can I access ERA?